Multiple U.S. health agencies have released HIV-specific information, and research on HIV and the novel coronavirus is trickling in. Here's what health care providers need to know.
New data presented at AIDS 2020 show the long-acting injectable drug cabotegravir proved superior to daily oral TDF/FTC for MSM and transgender women.
These studies presented at AIDS 2020 explore the benefits and challenges.
People living with HIV in the U.S. are experiencing increases in body mass index at a rate three times greater than that of the general U.S. population, according to new research presented at AIDS 2020.
Our Newest Posts
July 9, 2020: Abysmal HIV testing rates in U.S. ambulatory care settings; STI testing frequency in PrEP users; trends in U.S. PrEP uptake; integrating opioid therapy with HCV care in people who inject drugs.
A revolution in organ transplants is taking place.
Instead of only mourning the tragic murders, we need more programs to support the lives of Black and Brown transgender and gender nonconforming people.
July 1, 2020: Quantifying bone fracture risks; real-world lipid effects of switching to TAF; pulmonary function impairment in MSM; immunomodulatory drugs and viral load blips.
A newly published study linking HIV medication to reduction in COVID-19 risk has many problems, experts warn.
Legal groups provide pathways to reducing coronavirus spread in carceral settings.